Auguries of adaptivity: LES γδ TCR ligand recognition revisited.

Juliet L Gunn, Anzelika Rubina, Ceri A Fielding, Fiyaz Mohammed, Eddie C Y Wang, Carrie R Willcox, Benjamin E Willcox

Abstract readReview

In one paragraph

Review in Trends in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Juliet L GunnDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK; Cancer Immunology and Immunotherapy Centre, College of Medicine and Health, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, Birmingham, UK.

Anzelika RubinaDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Ceri A FieldingDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Fiyaz MohammedDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK; Cancer Immunology and Immunotherapy Centre, College of Medicine and Health, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, Birmingham, UK.

Eddie C Y WangDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Carrie R WillcoxDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK; Cancer Immunology and Immunotherapy Centre, College of Medicine and Health, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, Birmingham, UK.

Benjamin E WillcoxDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK; Cancer Immunology and Immunotherapy Centre, College of Medicine and Health, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, Birmingham, UK. Electronic address: b.willcox@bham.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of antigenic ligands for the γδ T cell receptor (TCR) has remained a highly challenging goal since the emergence in the 1980s of γδ T cells as a distinct immune compartment. In a significant advance more than 12 years ago, endothelial protein C receptor (EPCR), a cell-surface-expressed major histocompatibility complex (MHC)-like protein that binds phospholipids, was identified as the first ligand for a human γδ TCR to be validated by direct binding experiments: a finding that undoubtedly posed more questions than it answered. In this review we discuss how features of this single clonotypic specificity anticipated insights into adaptive-like human γδ T cell biology that emerged in subsequent investigations, and we highlight recent findings about EPCR that point towards the relevance of such responses in anti-pathogen and potentially anti-tumour immunity.

Indexed as

Receptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAnimalsEndothelial Protein C ReceptorHumansLigandsNeoplasmsProtein BindingEndothelial Protein C ReceptorLigandsReceptors, Antigen, T-Cell, gamma-deltaadaptive-likeclonal expansiondifferentiationligandmemoryT cell receptor (TCR)γδ T cells

Identifiers

PMID41330829

DOI10.1016/j.it.2025.10.006

PMCPMC7619023

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.